Key result
Tailored pharmacotherapy enhances management of inherited arrhythmia syndromes through deeper understanding of underlying mechanisms.
Answers are grounded in this paper and cite their sources.
This review summarizes current knowledge on the mechanistic basis and clinical evidence for tailored pharmacotherapy in managing inherited arrhythmia syndromes.
In the absence of structural heart disease, sudden cardiac death is frequently caused by inherited arrhythmia syndromes, such as long QT syndrome, Brugada syndrome and catecholaminergic polymorphic ventricular tachycardia. Managing these conditions often requires a combination of lifestyle modification, pharmacotherapy and less frequently, invasive therapy. Over the past decade, patient management has been greatly enhanced by tailored pharmacotherapy as a result of a deeper appreciation for arrhythmia mechanisms and supportive evidence from multicenter cohort studies. This article reviews current knowledge regarding drug therapy for inherited arrhythmias. Anti-arrhythmic mechanisms and available clinical evidence are highlighted while maintaining a practical perspective on patient management.
No takes yet. Share an insight, caveat, or question.
Tadros et al. (2015) conducted a review in Inherited arrhythmia syndromes. Pharmacotherapy was evaluated. Tailored pharmacotherapy for inherited arrhythmia syndromes has greatly enhanced patient management based on a deeper appreciation of arrhythmia mechanisms and clinical evidence.
Synapse has enriched 10 related papers. Consider them for comparative context: